B2B Lead Generation for Biotech, Pharma and Life Sciences Vendors

This page is for B2B suppliers whose customers are biotech companies, pharmaceutical manufacturers, medtech developers and the operations teams that run trials and plants. Contract research organisations, contract development and manufacturing organisations, analytical instruments, reagents, clinical trial software, quality and regulatory tooling, packaging and cold chain, and specialist engineering for GMP facilities.

We are not running direct-to-consumer prescription campaigns, patient-facing disease awareness ads, or broad "pharma marketing agency" brand work aimed at consumers. Some agencies use that phrase for drug branding. If that is your business, this page is the wrong fit. If you sell capability into R&D, clinical, manufacturing or quality, you are in the right place.

Buyer confusion is common. A lab equipment vendor and a patient recruitment vendor both say "life sciences", but the titles, compliance language and sales cycle are unrelated. We separate those motions in week one.

Adjacent pages: clinical providers and health systems sit under healthcare. GMP equipment and production suppliers often overlap manufacturing buyers; we still write to QA and site heads when the plant is pharma.

Lists are built around who can evaluate a vendor, run a pilot, or sign a master services agreement.

Research and early development:

• CSO, VP Research, heads of biology and chemistry, platform leads in discovery biotech.
• Lab operations and core facility managers who own instrument budgets.

Clinical development:

• VP Clinical Operations, directors of clinical trials, study managers and outsourcing leads.
• Pharmacovigilance and medical affairs when the product touches safety workflows (still B2B software or services, not consumer ads).

Manufacturing and quality:

• VP Manufacturing, head of MSAT, plant directors, head of quality and validation leads.
• Supply chain and procurement for raw materials, single-use systems and packaging.

Procurement and partnerships:

• Strategic sourcing for CRO and CDMO selection.
• Alliance management when the deal is a long-term manufacturing or development partnership.

Triggers we research from public sources:

• Trial registrations and phase transitions that imply outsourcing needs.
• Manufacturing expansions, facility announcements and hiring for GMP roles.
• Funding rounds for biotech with pipeline stage that matches your service (discovery vs phase III vs commercial).
• Quality or supply incidents reported in trade press (handled carefully, without alarmist copy).
• Technology migrations: LIMS, CTMS, eTMF and QMS hires that signal a stack change.

We do not reference non-public trial failures or patient identities. Compliance tone is factual and conservative.

Scientific buyers still read email when the subject line sounds like their programme, not like a webinar invite. A cold email agency programme uses dedicated domains, warmed mailboxes and 25 emails per mailbox per day. Growleady's floor is $2,500 per month USD (£2,000 per month UK) for roughly 10,000 sends a month.

Technical credibility matters. Copy is reviewed so claims match your regulatory positioning. We do not promise FDA outcomes, and trial results only appear when you have approved them. Suppression covers existing clients, active RFPs, competitors and opt-outs.

LinkedIn outreach reaches directors who publish hiring posts or conference activity. Profiles are tuned for scientific and operations credibility. LinkedIn starts at $1,500 per managed profile per month. Combined email and LinkedIn uses the email floor.

Cold calling is available when a sponsor or outsourcing lead is hard to reach in writing. Calling is quoted with the engagement; no published dial volume. UK screening includes TPS and CTPS where applicable.

Programme overview: B2B lead generation. Sending layer: cold email outreach.

Some teams ask whether we are a "pharma marketing agency" in the consumer sense. We are not. We are a B2B outbound partner for vendor revenue teams. If you also need congress booth creative or DTC media buying, that is a different supplier. If you need qualified meetings with clinical ops and manufacturing leaders, that is what we run.

Starting points only. Live campaigns use your validations, case studies and approved claims.

CRO / CDMO capacity. Reference a public pipeline stage or manufacturing announcement. Offer a short call on capacity and onboarding timelines for that modality, without quoting SLA numbers you cannot defend.

Lab instrumentation. Name the technique and the workflow (e.g. high-throughput screening, process analytical technology). Ask whether the lab is evaluating replacements this fiscal year.

Clinical software. Lead with the workflow burden (monitoring, TMF completeness, site payments). CTA is a 20-minute workflow review, not a generic demo.

GMP supplies. Write to manufacturing and procurement with qualification requirements you already meet. Ask who owns vendor approval for new materials at the site.

Regulatory consulting (B2B). Target heads of quality when a public inspection outcome or warning letter is already in the news. Tone is helpful, not punitive.

Reply rates on well-run programmes fall between 2% and 15%. Life sciences cycles are long; outbound creates qualified top-of-funnel meetings, not signed MSAs in week two.

Week 1 locks ICP by modality, geography, company stage and meeting definition. Week 2 builds verified lists, domains and LinkedIn assets. Week 3 launches sequences after legal and commercial review of claims.

First meetings typically land 2-3 weeks after launch. Follow-ups are essential; many scientific buyers reply after the third touch when a trial milestone is live.

Weekly reporting: replies, opt-outs, meetings booked and held, bounce rate, segment performance. Show-up rate across Growleady programmes is 85%+.

Figures on /proof/: 500+ B2B clients, $50M+ client-reported pipeline, 90% retention. They are not life-sciences-only statistics.

Book /book-a-call/ to see whether your offer, compliance constraints and average contract value suit outbound.

A single "life sciences" list is how vendors get ignored. Segmentation is built in week one.

Modality splits discovery biotech from commercial pharma from medtech hardware. CDMO outreach to a preclinical company uses different proof than capacity selling to a site with three commercial lines. Software sold to clinical ops is not pitched to manufacturing QA with the same deck.

Stage splits matter for service firms. Series A biology companies buy differently from phase III sponsors preparing for inspection. Funding news is useful only when paired with the service you actually deliver at that stage.

Site-level targeting is essential for instruments, consumables and GMP services. Corporate HQ emails often bounce to a black hole. We prioritise site quality, manufacturing and R&D operations contacts when your fulfilment is physical.

Procurement paths differ by company size. Top-20 pharma may require vendor onboarding before a pilot. Mid-size biotech may let the VP sign after one technical call. Sequences to procurement are longer and documentation-heavy; sequences to scientific sponsors are shorter.

Congress and trade show follow-up is a common ask. We can run post-event lists when you supply badge scans or attendee targets with consent cleared on your side. We do not scrape attendee lists from unofficial sources.

When your product touches healthcare delivery as well as drug development, we separate hospital buyers from sponsor buyers so compliance language stays accurate.

Average contract value guides intensity. A £50k instrument sale may justify fewer accounts and more touches per account. A high-volume consumable line may justify broader lists with tighter ICP filters. We align send volume with what your sales team can actually work.

Vendor organisations often need marketing, medical affairs or regulatory sign-off before copy goes live. Week three includes a review window for that process. We avoid comparative claims against named drugs, unapproved efficacy language and anything that sounds like patient advice. Outbound stays on operational value: time, quality, capacity, audit readiness, data integrity. Case studies use approved logos and metrics. If you only have anonymised proof, we write anonymised proof. Invented trial outcomes are never used. Scientific titles receive technically literate copy, not buzzwords. If your product requires an application scientist on the first call, we say so in the CTA so the meeting is staffed correctly. Long sales cycles get multi-threaded sequences: sponsor, ops lead and procurement may all receive coordinated mail that does not contradict. Sequences pause when your CRM shows an active RFP or incumbent renewal in progress. That coordination is how life sciences vendors keep outbound without annoying buyers who are already in contract. Vendor teams selling into both biotech startups and large pharma often split budgets by segment. We mirror that in reporting so your US discovery biotech lane can be scaled without touching EU manufacturing accounts until the bench is ready.

Email remains the highest-throughput channel for reaching directors who do not accept cold LinkedIn voice notes. Infrastructure, copy and reply SLAs match other B2B programmes: dedicated domains, warmed inboxes, 25 sends per mailbox per day, and suppression tied to your CRM.

LinkedIn is useful when sponsors post hiring or trial news on profile. It is priced from $1,500 per managed profile per month and should echo the same claims approved for email.

Calling is optional, quoted, and most often used when a timeline is tight (inspection prep, trial start, plant ramp). Show-up targets across Growleady programmes run 85%+ with confirmations handled by the pod.

First meetings usually appear 2-3 weeks after launch once setup is complete. Reply rates between 2% and 15% depend on list quality and seniority. A qualified meeting is defined in week one: right company stage, right site or HQ contact, and a conversation your AE or BD lead agreed to take.

For a wider managed motion see B2B lead generation. For email-specific scope see cold email outreach and the cold email agency page.